Arrowhead Research | ARWR - Current Liabilities


Arrowhead Research reported $194.53M in Current Liabilities for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 1.38B
Cash and Equivalent USD 129.79M
Current Assets USD 946.92M
Current Liabilities USD 194.53M
Debt USD 388.24M
EBIT USD -165.55M
EBITDA USD -159.33M
Employees 609
EPS Earnings Per Share USD -1.26
Equity Capital and Reserves USD 522.31M
Gross Profit on Sales USD 27.77M
Interest Expense on Debt USD 24.38M
Interest Income USD 9.62M
Loan Capital USD 200.33M
Market Capitalization USD 3.51B
Net Income USD -175.24M
Operating Expenses USD 193.32M
Operating Profit USD -165.55M
Ordinary Share Capital USD 138.14M
PE Price to Earnings USD 436.79
Pre-Tax Profit USD -179.09M
Sales Revenues USD 27.77M
Selling and Administration Expenses USD 30.95M
Stock USD -173.09M
Trade Creditors USD 33.05M
Trade Debtors USD 9.7M

Current Liabilities Change Date
Agios Pharmaceuticals USD 70.41M 18.04M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 225.22M Jun/2025
Arrowhead Research USD 194.53M 26.01M Jun/2025
Incyte USD 1.28B 608.18M Jun/2025
Ionis Pharmaceuticals USD 897.24M 646.94M Jun/2025
Ligand Pharmaceuticals USD 64.73M 6.05M Jun/2025
Merck USD 26.04B 863M Jun/2025
Moderna USD 1.57B 32M Jun/2025
Novartis USD 31.71B 95M Jun/2025
Sarepta Therapeutics USD 919.95M 314.36M Jun/2025
TG Therapeutics USD 171.89M 11.68M Jun/2025
Ultragenyx Pharmaceutical USD 293.24M 1.58M Jun/2025
Vertex Pharmaceuticals USD 4.14B 355.2M Jun/2025
Xencor USD 96.08M 7.65M Jun/2025